Table II.
OS (month) | PFS (month) | |||
---|---|---|---|---|
|
|
|||
Variable | STK11m | STK11wt | STK11m | STK11wt |
Chemotherapy (130) | ||||
First-line | 11.7 | 18.9 | 4.5 | 6.1 |
Second-line | 13.1 | 15.2 | 4.2 | 4.5 |
Immunotherapy (131) | ||||
First-line | 14.2 | 20.1 | 4.1 | 5.4 |
Second-line | 6.6 | 13.6 | 2.2 | 3.1 |
NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; STK11, serine/threonine kinase 11; STK11m, STK11 mutation; STK11wt, STK11 wild-type.